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SYNOPSIS
Many fungi cause pulmonary disease in HIV-infected patients. Major pathogens include
Pneumocystis jirovecii, Cryptococcus neoformans, Aspergillus species, Histoplasma capsulatum,
Coccidioides species, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Talaromyces
marneffei, and Emmonsia species. Because symptoms are frequently non-specific, a high index of
suspicion for fungal infection is required for diagnosis. Clinical manifestations of fungal infection
in HIV-infected patients frequently depend on the degree of immunosuppression and the CD4+ TH
cell count. Establishing definitive diagnosis is important because treatments differ. Primary and
secondary prophylaxis depends on CD4+ TH cell counts as well as geographic location and local
prevalence of disease.
Keywords
HIV; Opportunistic Infection; Pneumonia; Mycoses; Pneumocystis
The recognition of an outbreak of Pneumocystis pneumonia (PCP) in 1981 was a fraught
moment in the history of medicine.1 It heralded the coming HIV pandemic, a disease
heretofore unknown to humankind. Opportunistic fungal pathogens, Pneumocystis jirovecii
in particular, have contributed significantly to the morbidity and mortality of HIV-infected
patients. Fortunately, the development of and increasing access to effective combination
antiretroviral therapy (ART) have reduced the incidence of opportunistic infections in HIV-
infected patients worldwide. Nevertheless, fungi remain an important cause of disease,
especially for patients with undiagnosed HIV infection and for patients without access to, or
who fail to adhere to, ART.
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In immunocompetent hosts, an array of immune mechanisms averts disease caused by fungi.
Potential fungal pathogens are detected by pattern recognition receptors of innate immune
cells.2 These in turn produce cytokines, including IL-12, that result in activation of CD4+ TH
cells. Production of interferon-γ by TH1 cells then triggers cell-mediated, adaptive, cytotoxic
immunity. The downstream effects of interferon-γ production include recruitment of
leukocytes to the site of infection and enhanced macrophage phagocytosis and killing,
typically resulting in elimination of the invading fungi.3
The hallmark of HIV is infection of CD4+ TH cells and, to a lesser degree, other CD4+ cells
including macrophages. Left untreated, HIV disrupts the function of CD4+ TH cells and,
ultimately, depletes them. The consequences of HIV-mediated immune dysregulation are
wide ranging and include: decreased production of interferon-γ,4 impaired macrophage
phagocytosis,5 impaired neutrophil chemotaxis,6 impaired neutrophil oxidative killing,7 B
cell exhaustion, and decreased B cell antigen responsiveness.8 These defects in immunity
conspire against the host and result in susceptibility to opportunistic fungal infections.
Because the clinical presentation and radiographic findings of opportunistic fungal
infections are frequently non-specific, diagnosis relies on maintaining a high index of
suspicion. The intensity and duration of immunosuppression in HIV-infected patients is a
major risk factor. The likelihood of some infections, like PCP, is inversely related to a
patient’s CD4+ TH cell count; for other infections, like coccidioidomycosis, the clinical
manifestations differ among patients with lower CD4+ TH cell counts than for
immunocompetent patients. Diagnosis typically relies on identification of the fungus by
microscopy or culture, except in select instances where antigen or serum antibody testing
can be definitive.
This review discusses the clinical presentation, radiographic findings, diagnosis, and
management of selected respiratory fungal infections in patients with HIV. Particular
attention is extended to Pneumocystis pneumonia, which, in some geographic locales even
today, remains the most common AIDS-defining opportunistic infection.9
I. Pneumocystis pneumonia
A. Pneumocystis jirovecii
Pneumocystis is a genus of host obligate ascomycete fungus. There are numerous species of
Pneumocystis, each of which is specific to a particular mammalian host species.
Pneumocystis jirovecii infects and colonizes humans. It is host obligate, it cannot be cultured
or grown outside of the human body, and there is as yet no reliable evidence for an
environmental reservoir for this organism other than the human host.10–12
In immunocompetent humans, Pneumocystis does not cause any clear clinical syndrome.
Serologic studies indicate that humans are exposed to Pneumocystis as infants or young
children.13 Pneumocystis is unlikely to cause anything more than mild, self-limiting
respiratory symptoms.14,15 Animal models indicate that Pneumocystis is spread from host to
host via airborne transmission, and Pneumocystis jirovecii is likely spread among human
hosts in the same fashion.16 Most healthy adults do not have detectable Pneumocystis in
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respiratory specimens, but it is possible for immunocompetent adults, especially those with
chronic obstructive pulmonary disease (COPD) or cystic fibrosis, to harbor an asymptomatic
colonization with Pneumocystis. The consequences of chronic colonization may be
progressive impairment of lung function over time.17
By contrast, in immunocompromised hosts, Pneumocystis causes a devastating and
frequently fatal pneumonia. The risk of Pneumocystis pneumonia increases with the degree
of immunosuppression, and lower CD4+ TH cell counts predict risk of PCP. Among patients
with HIV, 95% of cases of PCP occur in patients with a CD4+ TH cell count less than 200
cells/μL; at a CD4+ TH cell count of 50 cells/μL, the risk of PCP is higher than at 100 cells/
μL or 200 cells/μL.18–20
B. What is the clinical presentation of Pneumocystis pneumonia?
The clinical presentation of PCP is non-specific and cannot reliably be distinguished from
other infectious pulmonary processes. Typical symptoms include fever, dyspnea, and a
cough that can be either non-productive or productive of scant sputum, but is rarely
purulent. Although the disease can be fulminant, PCP in patients with HIV frequently
presents with an indolent course. Patients may experience weeks of slowly progressive
symptoms, including a sensation of chest discomfort or chest tightness and exercise
intolerance.21 This is different from the presentation of PCP in medically
immunosuppressed patients without HIV infection, which is more frequently acute and may
rapidly progress to respiratory failure within days.22 Physical examination is also non-
specific. Chest auscultation may reveal end-inspiratory crackles, but is frequently normal.21
Severe disease may be characterized by signs of acute respiratory failure. Hypoxemia is
characteristic and can be mild (partial pressure of arterial oxygen when breathing room air
greater than 70 mm Hg and alveolar-arterial O2 difference less than 35 mm Hg), moderate
(alveolar-arterial O2 difference 35 to 45 mm Hg), or severe (alveolar-arterial O2 difference
greater than 45 mm Hg).23
C. What tests can be used for diagnosing Pneumocystis pneumonia?
There is no serologic test that is specific for PCP. Lactate dehydrogenase is a non-specific
biomarker of cell turnover and cellular damage, and serum levels are frequently elevated in
patients with PCP but are also elevated in the setting of other diseases including pneumonia
caused by bacteria, mycobacteria, and other fungi.24,25 (1–3) β-D-glucan is a component of
the fungal cell wall and can be detected in the serum of patients with PCP, but also does not
distinguish between PCP and other fungal pneumonias.26 These tests can be useful to
support a clinical suspicion for PCP but on their own are not specific enough for definitive
diagnosis in most cases.
Chest imaging has an important role in the diagnosis of PCP. The classic appearance of a
chest radiograph for a patient with PCP is diffuse, bilateral, interstitial type (commonly
described as reticular, granular, or “ground glass”) opacities (Fig. 1).27 However, the chest
radiograph in a patient with early disease may be normal; with late or severe disease, the
chest radiograph may show frank alveolar consolidation. Unusual but not inconsistent
features of PCP on chest radiography include focal asymmetric interstitial or alveolar
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opacities, nodules, pneumatoceles, cavities, and pneumothoraces.28 Computed high-
resolution tomography (HRCT) of the chest is a highly sensitive test for PCP with a high
negative predictive value. The classic appearance of PCP on a HRCT scan is bilateral,
frequently patchy but sometimes diffuse and homogenous, ground glass opacities (Fig. 2).29
Importantly, in a symptomatic patient with a normal chest radiograph, the absence of ground
glass opacities on HRCT significantly diminishes the probability of PCP. However, ground
glass opacities on HRCT are not specific for PCP and can be seen in other cardiopulmonary
pathology including viral pneumonia, pulmonary edema, and diffuse alveolar hemorrhage.30
As with chest radiography, a HRCT scan of the chest in advanced disease may show
consolidation, nodules, or pneumatoceles.
Because clinical presentation, serologic tests, and chest imaging are not definitive for PCP,
PCP is typically diagnosed by investigation of respiratory specimens. Appropriate
specimens include induced sputum or bronchoalveolar lavage (BAL) fluid. Pneumocystis is
rarely identified in spontaneously expectorated sputum. Diagnostic yield is higher with
induced sputum, that is sputum provoked by inhalation of an aerosol of hypertonic saline
solution, and sensitivity is 74–83%.31 However, a negative result for Pneumocystis in
induced sputum should be followed by bronchoscopy. In the hands of an experienced
cytopathologist, the sensitivity and specificity of BAL fluid obtained during fiberoptic
bronchoscopy approaches 100% for diagnosis of PCP.32
There is no method for culturing Pneumocystis so the principal diagnostic test is
cytopathologic examination. Diagnosis is established by the microscopic visualization of
trophic or cystic forms of Pneumocystis. A variety of histologic stains can be used to
identify Pneumocystis by light microscopy. The Diff-Quick and Wright-Giemsa stains
identify the nuclei of Pneumocystis organisms of all developmental stages. Grocott-Gomori
methenamine silver, toluidine blue O, and cresyl violet stain the wall of the cystic form but
not that of the trophic form. Other stains, such as the chemiflourescent calcofluor white (that
binds to beta-polymers of Pneumocystis and other fungi) and Papanicolau (which detects the
foamy eosinophilic exudate that surrounds Pneumocystis), can be used. The use of direct
fluorescent antibody stains for Pneumocystis which bind to both trophic and cystic forms
can increase sensitivity further.31
Molecular detection of Pneumocystis DNA by polymerase chain reaction (PCR) is offered
by some laboratories for use on respiratory specimens. While PCR testing is highly
sensitive, it has only moderate specificity for diagnosis of PCP. PCR testing detects the
presence of Pneumocystis DNA not only in those patients with pneumonia caused by
Pneumocystis, but also in patients who are merely colonized and who have symptoms that
can be attributed to another confirmed diagnosis or have no symptoms at all. A negative
PCR test, however, significantly decreases the likelihood that a patient has PCP.33,34
Diagnosis of PCP can be made by transbronchial biopsy through a fiberoptic bronchoscope
or by video-assisted thorascopic biopsy. Histopathologically, PCP is characterized by a
pattern of diffuse alveolar damage, a vacuolated and foamy exudate that fills alveolar
airspaces, a lymphocytic interstitial infiltrate, and hyperplasia of type 2 pneumocytes.
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Because of the high diagnostic yield of bronchoscopy with BAL, biopsy is seldom necessary
to confirm, or rule out, the diagnosis of PCP.
D. What are treatment options for Pneumocystis pneumonia?
If there is clinical suspicion for PCP in an HIV-infected patient, it is reasonable to initiate
empiric therapy while awaiting the results of diagnostic tests. Treatment need not be
deferred, since the yield for diagnosis of PCP from BAL fluid is unchanged for up to 14
days after starting treatment.23
The first choice of treatment is trimethoprim-sulfamethoxazole (TMP-SMX). The 1:5 fixed-
dose combination of TMP 15–20 mg/kg/day and SMX 75-100 mg/kg/day is given in 3–4
divided doses. It can be administered orally or intravenously (IV). Although oral
bioavailability is excellent, IV therapy is often preferred initially for cases of moderate to
severe PCP.35 The total recommended dose duration is 21 days; shorter courses have
resulted in higher rates of treatment failure.22 Use of TMP-SMX may be limited by adverse
reactions, including rash, fever, transaminitis, nephritis, hyperkalemia, and cytopenias.
There are alternative treatment options if TMP-SMX is not tolerated or if treatment fails. IV
pentamidine dosed at 4 mg/kg once daily has equivalent efficacy to IV TMP-SMX, but
greater toxicity.35,36 Adverse reactions include infusion site phlebitis, severe hypotension
during infusion, prolonged QT, torsades de pointes, pancreatitis, hypoglycemia,
transaminitis, nausea and vomiting, nephrotoxicity, hypocalcemia, hypomagnesemia,
hyponatremia, and leukopenia. Given the variety and severity of these toxicities, IV
pentamidine is typically reserved for patients with severe, life-threatening PCP who cannot
tolerate or are unresponsive to TMP-SMX.
Other alternative therapies include clindamycin with primaquine. Clindamycin can be
administered intravenously, 900 mg three times daily, or orally, 600 mg three times daily.
Primaquine is only available in an oral formulation and is given 30 mg once daily.35
Clindamycin with primaquine has equivalent efficacy to TMP-SMX for initial treatment of
mild to moderate PCP, and there is evidence to suggest that it is more effective than IV
pentamidine as a salvage therapy although there are no randomized controlled trials
comparing them.37
Oral dapsone 100 mg daily with TMP 15 mg/kg/day in three divided doses is as effective as
oral TMP-SMX for mild or moderate PCP but is ineffective for severe PCP. Atovaquone
suspension 750 mg orally, twice daily, is inferior therapy compared to TMP-SMX for mild
or moderate PCP and is ineffective for severe PCP.35
Adjunctive corticosteroids decrease need for ICU admission, mechanical ventilation, and
mortality in HIV-infected patients with moderate to severe PCP (partial pressure of arterial
oxygen when breathing room air less than 70 mm Hg or alveolar-arterial O2 difference
greater than 35 mm Hg).38,39 Ideally, steroids should be started at the time that
Pneumocystis-specific treatment is initiated, and definitely within the first 72 hours of
treatment. The recommended dosing schedule is 40 mg prednisone (or an equipotent dose of
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IV methylprednisolone) twice daily for 5 days, then 40 mg once daily for 5 days, and 20 mg
once daily for the remaining 11 days of treatment.35
With treatment, overall mortality from PCP in HIV-infected patients is about 10%. With
appropriate treatment, early clinical deterioration is common, attributed to a host
inflammatory response provoked by antibiotic-induced lysis of Pneumocystis organisms. If
there is no improvement or further clinical decline after at least 5 days of treatment,
treatment failure is a possibility and it would be reasonable to consider switching to an
alternative therapy, although other causes of clinical deterioration, such as iatrogenic
hypervolemia, pneumothorax, and methemoglobinemia, would need to be excluded.
E. When is prophylaxis appropriate and with what regimen?
The NIH, CDC, and IDSA consensus guidelines recommend PCP prophylaxis for patients
with CD4+ TH cell counts below 200 cells/μL. TMP-SMX is the preferred agent.
Traditionally, one double strength tablet (160 mg TMP and 800 mg SMX) once daily has
been the regimen of choice, but one single strength tablet (80 mg TMP and 400 mg SMX)
once daily is also effective. Alternatively, one double strength tablet can be taken three
times weekly. If TMP-SMX cannot be used because of adverse effects, alternative options
for prophylaxis include aerosolized pentamidine 300 mg once monthly; dapsone 100 mg
once daily; dapsone 50 mg once daily with pyrimethamine 50 mg once weekly; and
atovaquone 1500 mg oral suspension once daily. These regimens are less effective than
prophylaxis with TMP-SMX. PCP prophylaxis can be discontinued if the CD4+ TH cell
count increases to above 200 cells/μL for at least three months as a result of ART. Although
PCP can occur when CD4+ TH counts are greater than 200 cells/μL, the benefit of ongoing
PCP chemoprophylaxis is diminished and may be outweighed by the risk of drug toxicity.35
II. Cryptococcus
Cryptococcus is a genus of encapsulated yeast that is ubiquitous in human-populated
environments and can be isolated from bird excrement, rotting fruit, and soil.40 Some
species, such as Cryptococcus gatii, are known to cause disease in immunocompetent hosts.
The species that most frequently affects HIV-infected patients is Cryptococcus neoformans.
Although it is known to occasionally cause asymptomatic colonization in immunocompetent
hosts with structural lung disease, C. neoformans is almost exclusively an opportunistic
pathogen. A CD4+ TH cell count less than 100 cells/μL is a risk factor for cryptococcosis.41
C. neoformans gains access to the human host through inhalation of fungal basidospores.
Host immunosuppression allows C. neoformans to disseminate throughout the body. In
HIV-infected patients, cryptococcal meningitis is the most common manifestation. In
disseminated disease, multiple organs including the skin, bone, eye, prostate, and lung can
be affected. Although the respiratory system is the portal of entry, isolated cryptococcal
pneumonia without other organ involvement is less common than disseminated disease.42
Symptoms of cryptococcal pneumonia are non-specific and include cough, dyspnea, sputum
production, chest pain, and pleurisy. Findings on chest radiography are varied, and include
unilateral or bilateral interstitial opacities, focal consolidation, solitary or multiple
pulmonary nodules, cavitation, hilar adenopathy, and pleural effusion (Fig 3).43 Because of
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the severity of immunosuppression that permits invasive cryptococcosis, simultaneous co-
infection with other pulmonary pathogens is common.
The cryptococcal antigen (CrAg) test, which detects the presence of capsular
polysaccharides, is important for investigating cryptococcal infection. The test can be
performed on serum, cerebrospinal fluid, BAL fluid, or pleural fluid. The serum CrAg test is
highly sensitive for both cryptococcemia and cryptococcal meningitis; a negative serum
CrAg markedly decreases the likelihood of cryptococcal meningitis. The serum CrAg test is
often positive in cases of cryptococcal pneumonia, although it can be negative in cases of
isolated cryptococcal pneumonia without dissemination.43,44 The CrAg test can also be
performed on BAL fluid, although caution is warranted; in one study, the sensitivity of the
test was 71% and the positive predictive value was 0.59.45
Definitive diagnosis of cryptococcal pneumonia is typically made by cytopathologic
examination of a respiratory specimen, histopathologic examination of a biopsy specimen,
or culture of either. The yield of expectorated sputum is low; in one series, sputum
microscopy detected only one of 11 patients with cryptococcal pneumonia.46 BAL fluid is
significantly better with a diagnostic yield of 82%.44,46 The use of PCR for the detection of
Cryptococcus DNA in respiratory specimens is offered by some laboratories and appears
promising, but the clinical utility remains to be determined.47
There are no randomized controlled clinical trials for HIV-infected patients with isolated
cryptococcal pneumonia or disseminated cryptococcosis with pulmonary involvement.
Treatment recommendations are extrapolated from trials of treatment of cryptococcal
meningitis. For isolated pulmonary disease with mild symptoms, treatment with oral
fluconazole 400 mg daily for 12 months is recommended. For severe pulmonary disease or
disseminated disease, the standard initial (induction) treatment regimen is IV amphotericin
B and oral flucytosine for at least two weeks. If clinical improvement is noted, treatment can
be changed to consolidation therapy with oral fluconazole 400 mg daily for at least an
additional 8 weeks, followed by maintenance therapy with oral fluconazole 200 mg daily for
at least one year to prevent relapse. Extrapolating from data on patients who have recovered
from cryptococcal meningitis, secondary prophylaxis can be stopped if CD4+ TH counts are
greater than 200 cells/μL and the HIV viral load is undetectable for three months on ART.35
Current guidelines do not support primary prophylaxis of cryptococcal disease regardless of
CD4+ TH count. However, routine screening for asymptomatic cryptococcal antigenemia is
recommended by some experts for patients with a new diagnosis of HIV and a CD4+ TH
count less than 100 cells/μL. If the serum CrAg test is positive, CSF evaluation is required to
assess for meningitis. Asymptomatic cryptococcal antigenemia is treated with fluconazole
400 mg oral daily for 12 months.35
III. Aspergillus
Aspergillus is a genus of mold that is ubiquitous in the environment and can be isolated from
soil worldwide.48 Various species are known to cause human disease but the most frequent
pathogen is Aspergillus fumigatus. Human exposure to Aspergillus spp. occurs by inhalation
of airborne conidia. In immunocompetent hosts with normal lung architecture, it is rare for
Wang et al. Page 7
Clin Chest Med. Author manuscript.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Aspergillus to cause disease. In immunocompromised patients or patients with structural
lung abnormalities, Aspergillus is associated with several distinct chest syndromes:
aspergilloma, allergic bronchopulmonary aspergillosis (ABPA), tracheobronchial
aspergillosis, chronic necrotizing aspergillosis, and invasive pulmonary aspergillosis (IPA).
Different syndromes have unique risk factors. For aspergilloma, structural lung disease, like
bullae in chronic obstructive pulmonary disease, is a major predisposing condition. ABPA
has a predilection for patients with cystic fibrosis and severe asthma. IPA, the most severe
and most dangerous manifestation of Aspergillus infection, affects immunocompromised
hosts, particularly patients with absent or abnormal phagocyte function. The classic risk
factors for IPA are corticosteroid use and granulocytopenia from hematologic malignancy or
its therapies.49,50
All Aspergillus syndromes have been described in patients with HIV infection but compared
to the occurrence of other opportunistic pathogens, Aspergillus infection is uncommon.
While IPA was initially included as an AIDS-defining opportunistic infection by the Centers
for Disease Control, it was removed in 1984 when it was found that the incidence of IPA in
patients with HIV infection was 0.1 percent; incidence is lower still today because of
widespread use of effective ART.51 Even in patients with very low CD4+ TH counts, IPA is
unusual in the absence of additional risk factors such as neutropenia.
The clinical presentations of the various forms of Aspergillus-related disease in HIV-
infected patients are not distinct from those of HIV-uninfected patients, and are described
elsewhere in this volume. For invasive aspergillosis, patients with and without HIV can
present with fever, cough, dyspnea, pleurisy, and sometimes hemoptysis. Imaging findings
vary and can include consolidation, cavities, nodules, and pleural effusions. Definitive
diagnosis requires demonstration of tissue invasion on biopsy and isolation of the organism
by culture. In patients for whom biopsy is infeasible or fails to demonstrate invasive disease
but for whom IPA is still suspected, initiating empiric treatment for probable IPA is
reasonable. Voriconazole is the preferred therapy; alternative treatments include
amphotericin, caspofungin, or posaconazole.52 Given its low incidence even in advanced
HIV disease, prophylaxis is not recommended.35
IV. Endemic fungi
Around the world, there are pathogenic fungi that have limited geographic distribution.
These include Histoplasma capsulatum, Coccidioides species, Blastomyces dermatitidis,
Paracoccidioides brasiliensis, Talaromyces (formerly Penicillium) marneffei, and
Emmonsia species. These fungi are dimorphic. In the environment, they grow as molds. The
predominant method of human infection is through inhalation of spores from contaminated
soils. Once deposited in the human respiratory tract, the fungi change and grow as yeasts.
All are known to cause disease in immunocompetent hosts. Typically, the severity of disease
is related to the size of the inoculum as well as to the state of host immunity. In patients who
are immunocompromised, particularly with respect to cell-mediated immunity, infections
are more severe, more likely to disseminate beyond the respiratory system, and more
frequently fatal.
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Histoplasma capsulatum is found throughout the Americas, Africa, and Asia. It is endemic
to the Ohio and Mississippi River Valleys in the United States, as well as in regions of
Mexico, Venezuela, Brazil, Ecuador, Paraguay, Argentina, and Uruguay. In Asia, it is
endemic to parts of China, India, Thailand, and South Korea. Information is more limited
from Africa but cases have been reported from South Africa, Zimbabwe, Uganda, and
Tanzania.53 In immunocompetent hosts, histoplasmosis is typically a mild self-limited
respiratory illness characterized by fevers, chills, headache, myalgias, non-productive
cough, and chest pain that resolves over weeks. Immunocompromised patients, including
HIV-infected patients with CD4+ TH cell counts less than 150 cells/μL, are at risk for
disseminated histoplasmosis.54–57 In addition to cough and dyspnea, disseminated disease
presents with constitutional symptoms including fever and weight loss, as well as evidence
of other organ involvement including lymphadenopathy, hepatosplenomegaly, skin lesions,
meningitis, and infiltration of bone marrow. The tempo of illness can vary from indolent to
fulminant. Patterns on chest radiography associated with histoplasmosis include a diffuse
interstitial pattern or a military nodular pattern (Fig. 4). Less common but also compatible
are focal alveolar opacities or a normal chest radiograph. The Histoplasma antigen test can
be very helpful for diagnosis; in HIV-infected patients with disseminated disease, the
sensitivity of the urine Histoplasma antigen test approaches 100%, although the test may
also be positive in some patients with other endemic mycoses including blastomycosis,
coccidioidomycosis, paracoccidioidomycosis, and penicilliosis (talaromycosis).58 Antigen
testing in BAL fluid can be diagnostic, especially for relatively immunocompetent patients
with isolated pulmonary disease who may not have antigenuria or antigenemia.59 In
disseminated disease, fungal cultures are frequently positive from blood, bone marrow,
lymph node, and skin. Preferred treatment for disseminated histoplasmosis is IV liposomal
amphotericin B for at least two weeks or until evidence of clinical improvement, followed
by oral itraconazole for at least 12 months.35 Immunocompetent patients with mild
pulmonary disease can be treated with itraconazole for at least 12 weeks.60 Serial
Histoplasma urine or serum antigen levels can be used to monitor therapeutic response.
Primary prophylaxis for histoplasmosis is not recommended except for patients with CD4+
TH cell counts less than 150 cells/μL and who live in an area with hyperendemic rates of
histoplasmosis (greater than 10 cases/100 patient-years).35
Coccidioidomycosis is caused by two species of Coccidioides, C. immitis and C. posadasii.
They are endemic to semiarid regions of North and South America, including parts of
California, Arizona, New Mexico, Texas, Mexico, and Argentina. In immunocompetent
hosts, including HIV-infected patients with CD4+ TH cell counts greater than 250 cells/μL,
the spectrum of disease ranges from asymptomatic exposure to an influenza-like illness
characterized by fever, cough, fatigue, headache, and myalgia (colloquially called “valley
fever”) to frank pneumonia. In immunocompromised hosts, including HIV-infected patients
with CD4+ TH cell counts less than 150 cells/μL, Coccidioides spp. can disseminate causing
meningitis, lymphadenitis, hepatitis, and skin lesions.61,62 Disseminated disease frequently
presents with systemic symptoms including night sweats and weight loss. Radiographic
findings include diffuse nodular opacities, focal consolidation, solitary pulmonary nodules,
and cavitary lesions (Fig. 5). Definitive diagnosis is established by culture from infected
tissues or cyto- or histo-pathologic identification of pathognomonic giant spherules in
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sputum, BAL fluid, or biopsy specimens. Serologic tests are useful adjunctive tests.
Detection of Coccidioides-specific antibodies by complement fixation, enzyme
immunosorbent assay, or immunodiffusion can support a diagnosis of coccidioidomycosis
and can also be used to monitor response to treatment. Preferred treatment for severe or
disseminated coccidioidomycosis is amphotericin B.35 When clinical improvement is noted,
switching from amphotericin B to fluconazole or itraconazole for a minimum of another 12
months is appropriate .60 HIV-infected patients who have recovered from
coccidioidomycosis can be considered for secondary prophylaxis with fluconazole or
itraconazole if CD4+ TH cell counts remain less than 250 cells/μL. Current guidelines do not
support primary prophylaxis of coccidioidomycosis regardless of CD4+ TH count. However,
annual screening for Coccidioides exposure with an antibody test is recommended for
patients with a CD4+ TH count less than 250 cells/μL and who live in an endemic region.
Coccidioidal seroconversion is treated with daily oral fluconazole.35
Blastomyces dermatitidis is found primarily in North America along the Ohio, Mississippi,
and St. Lawrence Rivers. Blastomycosis is less common than either histoplasmosis or
coccidioidomycosis. In immunocompetent hosts, the manifestations of blastomycosis range
from asymptomatic infection to pneumonia to disseminated disease affecting the skin, bone,
genitourinary tract, and central nervous system. The frequency of severe or disseminated
disease is higher in immunocompromised hosts, including HIV-infected patients with CD4+
TH cell counts less than 200 cells/μL.63 Radiographic findings include diffuse interstitial
opacities, a military nodular pattern, focal or diffuse airspace consolidation, solitary of
multiple pulmonary nodules, mass lesions, or cavitary lesions.64 Definitive diagnosis is
established by culture of infected tissues or respiratory samples, including BAL fluid. In the
absence of a positive culture, histo- or cyto-pathologic identification of Blastomyces yeast
forms can support a diagnosis of blastomycosis. For severe life-threatening disease,
amphotericin B is the preferred treatment until there is evidence of clinical improvement,
followed by itraconazole for 6 to 12 months. For mild to moderate severity disease, initial
treatment with itraconazole is recommended for a duration of 6 to 12 months.60 Secondary
prophylaxis with itraconazole is recommended for HIV-infected patients with CD4+ TH cell
counts that remain less than 200 cells/μL. Current guidelines do not support primary
prophylaxis for blastomycosis regardless of CD4+ TH cell counts.60
Paracoccidioides brasiliensis is found throughout much of South and Central America, but
it is most common in parts of Brazil, Colombia, and Venezuela. The great majority of
infections are asymptomatic. Symptomatic disease is expected to manifest in 1% to 2% of
infected persons. There are two patterns of disease manifestation. Acute or juvenile
paracoccidioidomycosis occurs exclusively in children and young adults less than 30 years
of age, and is characterized by fever, weight loss, lymphadenopathy, hepatosplenomegaly,
and cytopenias as a result of disseminated disease within the reticuloendothelial system; the
illness evolves and progresses over weeks to months. Chronic or reactivation
paracoccidioidomycosis develops more slowly, over months, and can involve the lungs,
mucosa, skin, lymph nodes, adrenal glands, bones, and central nervous system.65 In HIV-
infected patients, paracoccidioidomycosis tends to be disseminated, more severe, and more
rapidly progressive.66–69 Chest radiograph findings vary and can include diffuse bilateral
reticular opacities, nodular opacities, airspace consolidation, cavitation, mediastinal
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adenopathy, and pleural effusion.69,70 Definitive diagnosis is typically established by
identification of Paracoccidioides yeast forms on microscopy of clinical specimens,
including sputum, BAL fluid, pleural effusion, lymph node aspirate, or tissue biopsy.67
Culture of the fungus is possible but can take several weeks so is clinically less useful.
Detection of specific serum antibodies by immunodiffusion is also diagnostic and reported
sensitivity is 90%.71 For severe life-threatening disease, amphotericin B is the preferred
treatment until there is evidence of clinical improvement, followed by itraconazole for 6 to
12 months. For mild to moderate disease, initial treatment with itraconazole is recommended
for 6 to 12 months.60 There are no specific recommendations for primary prophylaxis
against Paracoccidioides in HIV-infected patients although PCP prophylaxis with
trimethoprim-sulfamethoxazole may confer some protection as Paracoccidioides is
susceptible to sulfonamides.35
The causative agent for penicilliosis, previously known as Penicillium marneffei, was
determined to be substantially genetically different from other members of the Penicillium
genus and so was renamed Talaromyces marneffei in 2011.72 It is endemic to parts of Asia
including Vietnam, Thailand, Cambodia, Laos, Malaysia, Myanmar, Singapore, India,
China, Hong Kong, and Taiwan.73–76 Although penicilliosis can affect immunocompetent
patients, it is predominantly an opportunistic infection and symptoms are attributable to
disseminated infection.77 Clinical manifestations of penicilliosis are myriad and include
cough, fever, dyspnea, chest pain, lymphadenopathy, anemia, hepatosplenomegaly,
abdominal pain, diarrhea, skin and mucosal lesions, arthritis, and osteomyelitis.76 Chest
radiographic findings can mimic those of PCP, and include interstitial opacities, airspace
consolidation, pleural effusion, and cavitary lesions.77 Definitive diagnosis is made by
culture from blood or BAL, skin biopsy, bone marrow biopsy, or lymph node aspirate or
biopsy. Presumptive diagnosis can be made by microscopic examination of clinical
specimens, including BAL fluid. The preferred treatment is liposomal amphotericin B for at
least two weeks until clinical improvement, followed by oral itraconazole for 10 weeks.78
For HIV-infected patients, it is reasonable to provide secondary prophylaxis with
itraconazole for at least an additional 6 months and until CD4+ TH cell counts increase to
greater than 100 cells/μL.79 Primary prophylaxis is indicated for HIV-infected patients with
a CD4+ TH count less than 100 cells/μL and who reside or travel to endemic regions.35
At least four species of Emmonsia are known to be pathogenic in humans. Three species are
named: E. parva, E. crescens, and E. pasteuriana. E. parva and E. crescens cause
adiaspiromycosis, a pulmonary infection which is common in rodents but has been known to
affect immunocompetent humans as well. A striking feature of adiaspiromycosis is the
identification of giant conidia, or adiaspores, on microscopy, which neither replicate nor
disseminate but provoke a granulomatous response from the host. E. pasteuriana does not
cause adiaspiromycosis but, in case reports from Italy, Spain, China, and India, is described
to cause disseminated fungal disease in patients with cell-mediated immunodeficiency from
HIV infection, medical immunosuppression, or both.80–85 In 2013, a new species of an as
yet unnamed Emmonsia species of fungus was described in HIV-infected patients in South
Africa.86 In a case series of 54 patients, 51 were HIV-infected, one was medically
immunosuppressed following renal transplantation, and two had no apparent cause for
immunodeficiency.87 Genetically, the novel pathogen is more similar to E. pasteuriana and,
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unlike E. parva and E. crescens, it does not create adiaspores. For HIV-infected patients in
this case series, the median CD4+ TH count was 16 cells/μL; in 12 of the 51 HIV-infected
patients, symptomatic disease was likely provoked by immune reconstitution after initiation
of ART. Overall, 88% of the patients had lower respiratory disease as evidenced by chest
radiograph abnormalities including diffuse or focal opacities, lobar atelectasis, hilar
adenopathy, or an intrathoracic mass. Ninety-six percent of patients had cutaneous lesions,
ranging from papules, plaques, nodules, and ulcers, mimicking Kaposi’s sarcoma, varicella,
cutaneous tuberculosis, or syphilis. Other clinical features included fever, weight loss, night
sweats, and lymphadenopathy. Given the frequency of skin involvement, the most common
diagnostic procedure was skin biopsy which revealed yeast on histologic exam in 92% and
was culture positive in 72%. Organisms were also identified in respiratory tissue, bone
marrow, brain tissue, liver tissue, and blood. In total, 48% of patients died, half of them
before diagnosis was established. Most patients were treated with amphotericin B followed
by maintenance triazole therapy. However, much remains unknown about this new
pathogen, including whether it causes asymptomatic and self-limited infection in
immunocompetent hosts and its true geographic range. The final species name for this
pathogen remains to be determined.
V. Summary
Many fungi cause pulmonary disease in HIV-infected patients. Major pathogens include
Pneumocystis jirovecii, Cryptococcus neoformans, Aspergillus species, Histoplasma
capsulatum, Coccidioides species, Blastomyces dermatitidis, Paracoccidioides brasiliensis,
Talaromyces marneffei, and Emmonsia species. Because symptoms are frequently non-
specific, a high index of suspicion for fungal infection is required for diagnosis. Clinical
manifestations of fungal infection in HIV-infected patients frequently depend on the degree
of immunosuppression and the CD4+ TH cell count. Establishing definitive diagnosis is
important because treatments differ. Primary and secondary prophylaxis depends on CD4+
TH cell counts as well as geographic location and local prevalence of disease.
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KEY POINTS
1. Among HIV-infected patients, major fungal pathogens include Pneumocystis
jirovecii, Cryptococcus neoformans, Aspergillus species, Histoplasma
capsulatum, Coccidioides species, Blastomyces dermatitidis,
Paracoccidioides brasiliensis, Talaromyces marneffei, and Emmonsia
species.
2. Clinical manifestations of fungal infection in HIV-infected patients frequently
depend on the degree of immunosuppression and the CD4+ TH cell count.
3. Establishing definitive diagnosis is important because treatments differ.
4. Primary and secondary prophylaxis depends on CD4+ TH cell counts as well
as geographic location and local prevalence of disease.
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Figure 1.
Chest radiograph of a patient with newly-diagnosed HIV infection presenting with severe
PCP. There is diffuse bilateral interstitial shadowing, more marked on the left.
Courtesy of Robert F. Miller, MBBS CBiol FRSB FRCP; used with permission.
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Figure 2.
Axial HRCT of the upper chest of an HIV-infected patient with PCP. There are bilateral
patchy “ground glass” infiltrates, with sub-pleural sparing.
Courtesy of Robert F. Miller, MBBS CBiol FRSB FRCP; used with permission.
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Figure 3.
Chest radiograph of an HIV-infected patient with isolated cryptococcal pneumonia. There is
a focal consolidation in the right lower lobe with areas of cavitation.
Courtesy of Laurence Huang, MD; used with permission.
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Figure 4.
Chest radiograph of an HIV-infected patient with disseminated histoplasmosis
demonstrating diffuse interstitial opacities.
Courtesy of Laurence Huang, MD; used with permission.
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Figure 5.
Axial HRCT of the chest of an HIV-infected patient with coccidioidomycosis. There are
numerous nodules in a military pattern. Courtesy of Laurence Huang, MD; used with
permission.
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